Darrell H G Crawford

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1667676/publications.pdf

Version: 2024-02-01

55 papers	1,452 citations	331538 21 h-index	345118 36 g-index
55 all docs	55 docs citations	55 times ranked	2288 citing authors

#	Article	IF	Citations
1	CD73 and PD-L1 as Potential Therapeutic Targets in Gallbladder Cancer. International Journal of Molecular Sciences, 2022, 23, 1565.	1.8	7
2	APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. Hepatology International, 2022, 16, 1-23.	1.9	45
3	Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis. , 2022, 237, 108163.		4
4	Postâ€Traumatic stress disorder is associated with a higher rate of polypectomy independent of an increased frequency of colonoscopy in Australian Veterans â€“ a retrospective review. Internal Medicine Journal, 2022, , .	0.5	2
5	Polypharmacy in Australian Veterans with Post-traumatic Stress Disorder upon Admission to a Mental Health Facility: A Retrospective Chart Review. Drugs - Real World Outcomes, 2022, 9, 347-357.	0.7	1
6	Inhibition of MLKL Attenuates Necroptotic Cell Death in a Murine Cell Model of Hepatic Ischaemia Injury. Journal of Clinical Medicine, 2021, 10, 212.	1.0	9
7	Immune checkpoint molecules are regulated by transforming growth factor (TGF)-Î²1-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma. International Journal of Medical Sciences, 2021, 18, 2466-2479.	1.1	17
8	Combined Inhibition of TGF-Î²1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment. Journal of Clinical Medicine, 2021, 10, 1889.	1.0	25
9	Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: A Pilot Study. Journal of Clinical Medicine, 2021, 10, 2191.	1.0	9
10	Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells. Current Oncology, 2021, 28, 2150-2172.	0.9	9
11	Iron depletion attenuates steatosis in a mouse model of non-alcoholic fatty liver disease: Role of iron-dependent pathways. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166142.	1.8	10
12	Liver organoid as a 3D in vitro model for drug validation and toxicity assessment. Pharmacological Research, 2021, 169, 105608.	3.1	32
13	The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188451.	3.3	36
14	Assessment and Transplantation of Orphan Donor Livers: A Backâ€toâ€Base Approach to Normothermic Machine Perfusion. Liver Transplantation, 2020, 26, 1618-1628.	1.3	35
15	Therapeutic modulators of hepatic stellate cells for hepatocellular carcinoma. International Journal of Cancer, 2020, 147, 1519-1527.	2.3	25
16	Necroptosis in Hepatosteatotic Ischaemia-Reperfusion Injury. International Journal of Molecular Sciences, 2020, 21, 5931.	1.8	21
17	Imaging-based vascular-related biomarkers for early detection of acetaminophen-induced liver injury. Theranostics, 2020, 10, 6715-6727.	4.6	7
18	TNFâ€Î±â€‘mediated epithelialâ€‘toâ€‘mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma. Molecular Medicine Reports, 2020, 21, 1849-1860.	1.1	19

#	Article	IF	Citations
19	APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. Hepatology International, 2019, 13, 649-661.	1.9	72
20	Spotlight on Bortezomib: potential in the treatment of hepatocellular carcinoma. Expert Opinion on Investigational Drugs, 2019, 28, 7-18.	1.9	18
21	APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?. Hepatology International, 2019, 13, 103-109.	1.9	26
22	Ferroportin Expression in Adipocytes Does Not Contribute to Iron Homeostasis or Metabolic Responses to a High Calorie Diet. Cellular and Molecular Gastroenterology and Hepatology, 2018, 5, 319-331.	2.3	14
23	Concise Review: Quantitative Detection and Modeling the In Vivo Kinetics of Therapeutic Mesenchymal Stem/Stromal Cells. Stem Cells Translational Medicine, 2018, 7, 78-86.	1.6	38
24	Detailed Polysomnography in Australian Vietnam Veterans With and Without Posttraumatic Stress Disorder. Journal of Clinical Sleep Medicine, 2018, 14, 1577-1586.	1.4	11
25	Iron Inhibits the SecretionÂof Apolipoprotein E in Cultured Human Adipocytes. Cellular and Molecular Gastroenterology and Hepatology, 2018, 6, 215-217.e8.	2.3	10
26	Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma. Frontiers in Oncology, 2018, 8, 269.	1.3	106
27	Evaluation of a bone morphogenetic protein 6 variant as a cause of iron loading. Human Genomics, 2018, 12, 23.	1.4	8
28	Visualizing liver anatomy, physiology and pharmacology using multiphoton microscopy. Journal of Biophotonics, 2017, 10, 46-60.	1.1	31
29	Serum ferritin concentration predicts hepatic fibrosis better than hepatic iron concentration in human <scp>HFE</scp>â€Haemochromatosis. Liver International, 2017, 37, 1382-1388.	1.9	21
30	Two-photon dual imaging platform for in vivo monitoring cellular oxidative stress in liver injury. Scientific Reports, 2017, 7, 45374.	1.6	35
31	Visualization and Modeling of the In Vivo Distribution of Mesenchymal Stem Cells. Current Protocols in Stem Cell Biology, 2017, 43, 2B.8.1-2B.8.17.	3.0	3
32	Lowâ€Ðose Lipopolysaccharide Causes Biliary Injury by Blood Biliary Barrier Impairment in a Rat Hepatic Ischemia/Reperfusion Model. Liver Transplantation, 2017, 23, 194-206.	1.3	4
33	The Implications of the Shift Toward Donation After Circulatory Death in Australia. Transplantation Direct, 2017, 3, e226.	0.8	9
34	A physiologically based kinetic model for elucidating the in vivo distribution of administered mesenchymal stem cells. Scientific Reports, 2016, 6, 22293.	1.6	23
35	Heterozygous Hfe gene deletion leads to impaired glucose homeostasis, but not liver injury in mice fed a high-calorie diet. Physiological Reports, 2016, 4, e12837.	0.7	5
36	APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatology International, 2016, 10, 681-701.	1.9	75

#	Article	IF	Citations
37	APASL consensus statements and recommendation on treatment of hepatitis C. Hepatology International, 2016, 10, 702-726.	1.9	189
38	Probiotics modify tight-junction proteins in an animal model of nonalcoholic fatty liver disease. Therapeutic Advances in Gastroenterology, 2016, 9, 463-472.	1.4	37
39	Should HFE p.C282Y homozygotes with moderately elevated serum ferritin be treated? A randomised controlled trial comparing iron reduction with sham treatment (Mi-iron). BMJ Open, 2015, 5, e008938.	0.8	12
40	Assessing Steatotic Liver Function after Ischemia-Reperfusion Injury by In Vivo Multiphoton Imaging of Fluorescein Disposition. Drug Metabolism and Disposition, 2015, 43, 154-162.	1.7	19
41	Next-generation sequencing: Application of a novel platform to analyze atypical iron disorders. Journal of Hepatology, 2015, 63, 1288-1293.	1.8	24
42	Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries. Hepatology International, 2015, 9, 486-507.	1.9	18
43	Real-time histology in liver disease using multiphoton microscopy with fluorescence lifetime imaging. Biomedical Optics Express, 2015, 6, 780.	1.5	42
44	Multiphoton microscopy in defining liver function. Journal of Biomedical Optics, 2014, 19, 090901.	1.4	35
45	Interleukin-28B rs12979860 C allele: Protective against advanced fibrosis in chronic hepatitis C genotype 1 infection. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1458-1462.	1.4	4
46	Early on-treatment viral load and baseline METAVIR score: improved prediction of sustained virological response in HCV genotype 1 patients. Antiviral Therapy, 2012, 17, 849-854.	0.6	2
47	Iron Predicts Tolerance in Liver Transplantation. Gastroenterology, 2012, 143, 862-865.	0.6	0
48	Serum ferritin concentration predicts mortality in patients awaiting liver transplantation. Hepatology, 2010, 51, 1683-1691.	3.6	70
49	Reply: Ferritin and Liver Allocation? Impact on Mortality Not Only on the Waiting List But Also After Orthotopic Liver Transplantation Should Be Considered. Hepatology, 2010, 52, 393-393.	3.6	0
50	Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis. Hepatology, 2009, 49, 418-425.	3.6	46
51	Cellâ€specific location of Hfe: It is the 'cyte that matters. Hepatology, 2008, 48, 336-338.	3.6	0
52	Patient and graft survival after liver transplantation for hereditary hemochromatosis: Implications for pathogenesis. Hepatology, 2004, 39, 1655-1662.	3.6	108
53	Hepatocellular carcinoma in Australia: largely preventable?. Medical Journal of Australia, 2000, 173, 396-397.	0.8	1
54	Glomerular abnormalities in children undergoing orthotopic liver transplantation. Pediatric Nephrology, 1992, 6, 407-411.	0.9	13

#	Article	IF	Citations
55	Current Concepts in Rational Therapy for Haemochromatosis. Drugs, 1991, 41, 875-882.	4.9	10